Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

BIVI - BioVie Inc. Последние новости | Finranks

Home

BIVI

(BIVI)

NCM – Цена в реальном времени. Валюта: USD

1.36

0.00 (0.00%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

1.41

+0.05 (3.68%)

После закрытия: Mar 27, 2026, 7:33 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

BioVie targets Parkinson's at its source with lead drug bezisterim

BioVie targets Parkinson's at its source with lead drug bezisterim

For decades, treatment of Parkinson's disease has centered on replacing dopamine, the neurotransmitter whose decline drives the disease's hallmark motor symptoms. But while therapies such as levodopa can temporarily restore movement, they do little to address the underlying neurodegeneration, and often introduce complications of their own.

BioVie to present Parkinson's study data at AD/PD 2026 conference

BioVie to present Parkinson's study data at AD/PD 2026 conference

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that an abstract from its SUNRISE-PD study evaluating its lead candidate bezisterim (NE3107) for Parkinson's disease has been accepted for presentation at the AD/PD 2026 Advances in Science & Therapy annual meeting. The conference is scheduled to take place March 17 to 21, 2026, in Copenhagen, Denmark.

BioVie Inc. (BIVI) Discusses Clinical Progress of Bezisterim Targeting Inflammation in Parkinson's, Alzheimer's, and Long COVID Transcript

BioVie Inc. (BIVI) Discusses Clinical Progress of Bezisterim Targeting Inflammation in Parkinson's, Alzheimer's, and Long COVID Transcript

BioVie Inc. (BIVI) Discusses Clinical Progress of Bezisterim Targeting Inflammation in Parkinson's, Alzheimer's, and Long COVID Transcript

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights

BioVie highlights bezisterim research at ACP meeting

BioVie highlights bezisterim research at ACP meeting

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Thursday that two abstracts highlighting research on its lead drug candidate bezisterim (NE3107) have been accepted for presentation at the 2026 American College of Psychiatrists annual meeting in Bonita Springs, Florida. The abstracts, which focus on bezisterim's potential in Alzheimer's disease and Long COVID, will be presented as posters on February 18.

BioVie could offer first new Parkinson's therapy in decades

BioVie could offer first new Parkinson's therapy in decades

In biotech, the most compelling investment stories often emerge where medical need, scientific differentiation, and timing intersect. BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW), a clinical-stage biopharmaceutical company with a market capitalization still measured in the tens of millions, is attempting exactly that by targeting what it believes is a root driver of neurodegeneration rather than merely treating symptoms.

BioVie hits enrolment milestone in early Parkinson's trial, data due later this year

BioVie hits enrolment milestone in early Parkinson's trial, data due later this year

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed enrolment in a closely watched mid-stage trial testing whether its experimental drug bezisterim can slow the progression of early Parkinson's disease, putting the group on track for key data later this year. The Phase 2 study, known as SUNRISE-PD, has enrolled 60 patients who were diagnosed within the past four years and have not yet been treated with standard levodopa therapy.

Видео

No Data

There is no data to display